This is a vaccine treatment design based on specific CTLs against EML4-ALK positive cancer cells, and further research and analysis are still required in order to realize the application of this type of vaccine in ALK positive NSCLC patients. This evidence concerns the gene EML4 and non-small cell lung carcinoma.